As per our report, the size of the Asia Pacific Thyroid Cancer Market was valued at USD 46.38 million in 2020 and is expected to grow at a CAGR of 30.16% to reach USD 173.26 million by 2025.
Thyroid cancer is basically treated by surgery and radiotherapy. Chemotherapy has fewer roles in the treatment. Doxorubicin is said to be used as an off-label drug for treating plastic thyroid cancer patients. In the same way some other off-name medications, for example, carboplatin and cisplatin are used, however response rates have come down because of them. It can be concluded that Asia Pacific Thyroid Cancer Market is expected to have a high growth rate.
Asia Pacific Thyroid Cancer Market is strong because it consists of 27 molecules that are in different stages of development. There are four molecules in Pre-registration (1) and Phase III (3). These drugs mostly get approved in the next 7 years. XL184, Zactima, and Zybrestat have been granted orphan drug status by the FDA.
Once the above molecules get approved, it will intensify competition in the market which in turn results in substantial growth in market. Current competition in Asia Pacific Thyroid Cancer Market is very less. Some effective treatments like surgery exist and chemotherapy drugs can be used. Companies such as Doxorubicin which aim at managing conditions are prone to get larger success in the future.
This research report on the Asia Pacific Thyroid Cancer Market segmented and sub-segmented into the following categories.
By Treatment:
By Drug:
By End User:
By Country:
Noteworthy players dominating the APAC Thyroid Cancer Market profiled in this report are Baxter International Inc., Mylan Pharmaceuticals Inc., Alara Pharmaceutical Corporation, Bristol Myers co, Abbott laboratories, Teva parenteral medicines Inc., App pharmaceuticals LLC, and Jerome Stevens Pharmaceuticals Inc.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Treatment
5.1.1 Introduction
5.1.2 Surgery
5.1.3 Iodine Theraphy
5.1.4 External radiotherapy
5.1.5 Thyroxine treatment
5.1.6 chemotherapy
5.1.7 Drugs
5.1.8 Y-o-Y Growth Analysis, By Treatment
5.1.9 Market Attractiveness Analysis, By Treatment
5.1.10 Market Share Analysis, By Treatment
5.2 End User
5.2.1 Introduction
5.2.2 Hospital
5.2.3 Oncology centers
5.2.4 Hospital Pharmacies
5.2.5 Retail Pharmacies
5.2.6 Y-o-Y Growth Analysis, By End User
5.2.7 Market Attractiveness Analysis, By End User
5.2.8 Market Share Analysis, By End User
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Treatment
6.1.3.3 By End User
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Treatment
6.1.4.3 By End User
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Treatment
6.1.5.3 By End User
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Baxter International Inc
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Mylan pharmaceuticals Inc
8.3 Alara Pharmaceutical Corporation
8.4 Bristol Myers co
8.5 Abbott laboratories
8.6 Teva parenteral medicines Inc
8.7 App pharmaceuticals llc
8.8 Jerome Stevens Pharmaceuticals Inc
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Feb 2020
